Pharmacology of Antisense Therapeutic Agents: Cancer and Inflammation
C. Frank Bennett(Pennsylvania State University), Brett P. Monia(Ionis Pharmaceuticals (United States)), Nicholas Dean(Ionis Pharmaceuticals (United States)), David J. Ecker(University of Colorado Denver)
Cited by 35
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
A Multiubiquitin Chain Is Confined to Specific Lysine in a Targeted Short-Lived Protein
|Science|1989|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k